Hormonal
SGLT-2 inhibitor monotherapy produces only moderate weight loss (1.5–2 kg) in obesity because it triggers counter-regulatory mechanisms that increase appetite and energy intake, offsetting the caloric deficit from glucosuria.
If you use an SGLT-2 inhibitor (like Jardiance or Farxiga) for weight loss, expect a modest drop of 1.5–2 kg. Your body will likely try to counteract this by making you hungrier. To get significant weight loss, this medication is rarely enough on its own; it works best when combined with drugs that suppress appetite (like GLP-1 agonists) or lifestyle changes that actively manage hunger.
SGLT2 inhibitors cause substantially less weight loss than expected from the energy excreted via glycosuria, because it elicits an adaptive increase in energy intake, including compensatory increases in appetite/caloric intake [40].
Why this rating
Based on network meta-analyses and multiple clinical trials cited in the text.
Source
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al. · Drugs · 2019
DOI 10.1007/s40265-019-1057-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →